At the Advances in Genome Biology and Technology, AGBT, General Meeting, 10x Genomics (TXG) announced a series of new product innovations to ...

General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

and the pricing challenges from the GEM-X transition are expected to ease by the fourth quarter. William Blair keeps the ...

The Genomics Core houses a 10X Genomics Chromium iX which has the capacity to prepare GEMs for all standard 10X Genomics single cell pipelines: 3" scRNAseq single cell immune profiling fixed RNA ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $25.00 to $12.00 in a research report on Thursday.

Analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of 10x Genomics in a research note issued to investors on Thursday, February 13th. Leerink Partnrs analyst P. Souda ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled two-week trial, according to a Thursday filing in Delaware ...